GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Processa Pharmaceuticals
The shares of Processa, an oncology biotech, reflect the potential of its pipeline. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage pharmaceutical company developing drugs to treat oncological diseases requiring novel approaches. We've categorized it under "Breast Cancer." The chart below shows how the market values small biotech companies with niche developments.
Broad Market Index - GURU.Markets
Processa Pharmaceuticals is a biopharmaceutical company developing drugs to treat oncology conditions with unmet medical needs. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Processa compares to it.
Change in the price of a company, segment, and market as a whole per day
PCSA - Daily change in the company's share price Processa Pharmaceuticals
For Processa Pharmaceuticals, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Breast cancer
Processa Pharmaceuticals focuses on oncology, which means it experiences high volatility tied to clinical trial results. The chart below shows the average daily risk in this sector. It serves as a benchmark for understanding how PCSA shares compare to the norm for biotech.
Daily change in the price of a broad market stock, index - GURU.Markets
Processa Pharmaceuticals is a biotech company focused on women's health, particularly cancer treatment. Its shares are highly volatile and dependent on clinical trial results. These scientifically based movements are part of the complex picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Processa Pharmaceuticals
Processa Pharmaceuticals' year-to-date performance tells the story of its unique drug development strategy. Its 12-month market cap depends on progress in clinical trials, where it leverages its pharmacological expertise to improve and repurpose existing drugs for the treatment of cancer and other diseases.
Annual dynamics of market capitalization of the market segment - Breast cancer
As an early-stage biotech company, Processa is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Processa Pharmaceuticals is a focused bet on beating cancer. Its stock price is completely uncorrelated with the market, but is a direct response to the clinical trial data of its drugs. Its earnings chart is a heartbeat of patient and investor hopes, where scientific data is king.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its cancer drugs triggers an immediate and strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Breast cancer
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs to treat oncology conditions with unmet needs. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its drugs designed to improve the effectiveness of chemotherapy in trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Processa Pharmaceuticals is a biotech company whose stock is preoccupied with the results of clinical trials. Its monthly performance is completely disconnected from the market and is driven by drug development news. The chart clearly illustrates that for such companies, trial data is more important than the overall economic situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage oncology company. Its weekly stock price, like that of other biotechs, is entirely dependent on clinical trial results, which can lead to sharp upswings or downswings.
Weekly dynamics of market capitalization of the market segment - Breast cancer
Processa Pharmaceuticals focuses on cancer treatments. For companies like this, clinical trial news is key. The chart shows whether Processa's weekly share price surge is a one-off or reflects overall investor sentiment in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Processa Pharmaceuticals is an oncology biotech company. Its success depends on scientific breakthroughs. The chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
PCSA - Market capitalization of the company Processa Pharmaceuticals
Processa Pharmaceuticals' chart is a story of drug repurposing. The company's market cap reflects its strategy of taking existing drugs and developing them to treat new oncological diseases. This is an attempt to mitigate the risks inherent in pharmaceutical R&D.
PCSA - Share of the company's market capitalization Processa Pharmaceuticals within the market segment - Breast cancer
Processa Pharmaceuticals is a biopharmaceutical company specializing in developing drugs for the treatment of breast cancer and other oncological diseases. In this segment, its market capitalization reflects the potential of its drug candidates. The dynamics of this metric are a sensitive barometer of clinical trial news.
Market capitalization of the market segment - Breast cancer
Processa Pharmaceuticals develops oncology drugs. How big is this arena? The chart below shows the pulse of the breast cancer treatment sector. Its high volatility reflects both the enormous hopes for new drugs and the high risks associated with their development and clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Processa Pharmaceuticals chart shows how the market values a biotech company focused on developing oncology drugs. Its market cap is a bet on the success of its drugs in clinical trials. The chart's dynamics visualize the risks and hopes associated with cancer treatment.
Book value capitalization of the company, segment and market as a whole
PCSA - Book value capitalization of the company Processa Pharmaceuticals
Processa Pharmaceuticals' book value is its tangible assets, which consist of a pipeline of cancer drug candidates and the financial reserves needed to advance them through clinical trials. The chart below shows how this scientific and financial capital has changed.
PCSA - Share of the company's book capitalization Processa Pharmaceuticals within the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage pharmaceutical company. Its tangible assets are research laboratories focused on developing drugs for oncology and other diseases. The chart shows the share of this specialized R&D infrastructure the company controls in its therapeutic niche.
Market segment balance sheet capitalization - Breast cancer
Processa Pharmaceuticals is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Processa focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Processa's assets are not its factories, but rather its team of specialists and capital, which are used to conduct clinical trials of cancer drugs licensed from other companies. Its book value reflects its financial resources for refining these drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Processa Pharmaceuticals
Processa Pharmaceuticals develops drugs, optimizing their dosage and administration. Its value lies in its regulatory expertise. The chart shows how the market values its ability to "rescue" and improve drugs developed by others.
Market to book capitalization ratio in a market segment - Breast cancer
Processa Pharmaceuticals is a pharmaceutical company specializing in developing drugs for the treatment of oncology diseases. Its value depends on the success of its clinical programs. The chart shows how investors value its development pipeline.
Market to book capitalization ratio for the market as a whole
Processa Pharmaceuticals develops cancer drugs. Its entire value comes from the intellectual property and potential of its drug candidates. This chart illustrates how, in oncology biotech, market valuation reflects investor hopes for the development of new, effective treatments.
Debts of the company, segment and market as a whole
PCSA - Company debts Processa Pharmaceuticals
Processa Pharmaceuticals is a pharmaceutical company that specializes in rescuing and developing drugs abandoned by other companies. This strategy requires capital to conduct new clinical trials and navigate the regulatory process. This chart shows how the company finances its unique business model in the pharmaceutical industry.
Market segment debts - Breast cancer
Processa Pharmaceuticals is a clinical-stage oncology company that specializes in repurposing existing drugs to treat new types of cancer. This model can reduce development time and costs. This chart shows its financial status and how it funds its clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in oncology. This chart shows its financial structure. For a company whose future depends entirely on the results of clinical trials, debt is a huge risk that could lead to bankruptcy if the results are unsuccessful.
Market segment debt to market segment book capitalization - Breast cancer
Processa Pharmaceuticals specializes in developing cancer treatments, particularly for patients in need of new therapeutic options. The chart shows the overall debt burden in the pharmaceutical industry, providing investors with context for assessing the company's financial strategy during its long and risky clinical research journey.
Debt to book value of all companies in the market
Processa Pharmaceuticals is a clinical-stage oncology company specializing in cancer treatments. This chart clearly demonstrates that the debt market is closed to such innovative but not yet profitable companies. Their survival and growth depend entirely on their ability to attract equity capital to fund their research.
P/E of the company, segment and market as a whole
P/E - Processa Pharmaceuticals
For Processa Pharmaceuticals, an oncology company, the P/E ratio is irrelevant. The company has no stable profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' faith in the success of its drugs in clinical trials.
P/E of the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for oncology diseases with unmet needs, particularly breast cancer. This chart shows the average valuation for the sector, providing investors with context for evaluating Processa's portfolio.
P/E of the market as a whole
Processa Pharmaceuticals is a biopharmaceutical company specializing in the development of oncology treatments. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Processa Pharmaceuticals
Processa Pharmaceuticals is a biopharmaceutical company developing drugs to treat oncological diseases in need of improved therapeutics. This chart reflects investor expectations for its clinical programs. This valuation is based on the potential of its drugs to improve the efficacy and safety of existing cancer treatments.
%20P%2FE%20Processa%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Processa-Pharmaceuticals&v=1772513424756 "Chart of the company's future (projected) P/E Processa Pharmaceuticals")
Future (projected) P/E of the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on oncology treatments. Its valuation relative to other biotechs reflects investor opinions on its approach to drug development. This reflects how the market evaluates its ability to identify promising molecules and successfully conduct clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Breast-cancer&v=1772513424771 "Future (projected) P/E graph of the market segment - Breast cancer")
Future (projected) P/E of the market as a whole
Processa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of cancer, particularly breast cancer. Its development pipeline is in the clinical stage. This chart shows the overall investor risk appetite, which is a key factor in funding companies operating in such a competitive and complex field as oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513424810 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage oncology company that acquires and develops drugs for the treatment of cancer, particularly breast cancer. The financial metrics presented here represent investments in clinical trials of these promising but risky assets.
Profit of companies in the market segment - Breast cancer
Processa Pharmaceuticals specializes in developing drugs to treat breast cancer. This chart shows overall profitability in the oncology sector. It helps assess how competitive this specific, yet crucial, field is and which treatment approaches are the most commercially promising.
Overall market profit
Processa Pharmaceuticals is an oncology company developing drugs for the treatment of breast cancer. Its value depends entirely on the results of clinical trials and FDA approval. The demand for effective cancer drugs is not dependent on economic cycles, so this schedule is irrelevant for PCSA.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Processa Pharmaceuticals
Processa Pharmaceuticals is an oncology company specializing in developing drugs for the treatment of breast cancer. Its future profit forecast depends on the success of its clinical programs. This chart reflects analyst expectations for its drug candidates and their market potential.
%20profit%20of%20the%20company%20Processa%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Processa-Pharmaceuticals&v=1772513424855 "Graph of future (projected) profit of the company Processa Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Breast cancer
Processa Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of oncology, particularly breast cancer. The company often licenses and develops drugs that have already completed early-stage research. This chart shows forecasts for this segment, helping to assess how this business model impacts the company's risks and potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Breast-cancer&v=1772513424863 "Graph of future (predicted) profits of companies in a market segment - Breast cancer")
Future (predicted) profit of the market as a whole
For Processa Pharmaceuticals, a company focused on cancer treatment, this chart is important for access to funding. A positive market outlook facilitates raising capital for clinical trials. A negative trend and risk aversion could make it more difficult to secure capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513424864 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Processa Pharmaceuticals
Processa Pharmaceuticals is an oncology company focused on developing treatments for patients in need of better treatment options. This metric reflects investors' assessment of its clinical pipeline and potential future revenue.
P/S market segment - Breast cancer
Processa Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of cancer, particularly breast cancer. This chart shows the average valuation in the oncology sector. It reflects investor expectations for the potential of Processa's drugs and the risks associated with their clinical development.
P/S of the market as a whole
Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing drugs to treat oncology conditions with unmet needs. The company's valuation is based on the combined potential of its pipeline. This chart helps assess the risks and potential rewards in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Processa Pharmaceuticals
Processa Pharmaceuticals is an oncology company focused on developing drugs for the treatment of breast cancer and other solid tumors. Its valuation is dependent on the success of clinical trials. The chart reflects investor confidence in its scientific approach and the potential of its drug candidates.
%20P%2FS%20Processa%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Processa-Pharmaceuticals&v=1772513424938 "The graph of the company's future (projected) P/S Processa Pharmaceuticals")
Future (projected) P/S of the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage pharmaceutical company that acquires and develops drugs for the treatment of oncology diseases, particularly cancers requiring specific dosing approaches. This chart shows how investors view its strategy and development pipeline compared to other oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20Breast%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Breast-cancer&v=1772513424950 "Future (projected) P/S market segment graph - Breast cancer")
Future (projected) P/S of the market as a whole
This chart illustrates investor sentiment in the oncology field. For Processa Pharmaceuticals, a company developing drugs to treat breast cancer, it's an indicator of the investment climate. Market optimism helps attract funding for clinical trials aimed at improving treatment outcomes for a large group of patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513424982 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage pharmaceutical company developing drugs to treat oncological diseases for which there are currently no effective treatment options. This chart reflects revenue from grants and partnerships. Future revenue is dependent on the success of clinical trials of its targeted therapies.
Sales of companies in the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage pharmaceutical company developing drugs for the treatment of oncology diseases, particularly breast cancer. This chart shows financial activity in this sector. Processa focuses on improving the efficacy and safety of chemotherapy, solving one of the key challenges in cancer treatment.
Overall market sales
Processa Pharmaceuticals is a clinical-stage oncology company specializing in breast cancer treatments. Its growth depends on successful research. The overall economic environment, shown in this chart, impacts the availability of capital to fund innovative approaches to treating common cancers.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Processa Pharmaceuticals
Processa Pharmaceuticals is an oncology company developing cancer treatments, with a particular focus on patients who do not respond to standard chemotherapy. This chart reflects analyst expectations for the success of its clinical programs in the treatment of resistant forms of cancer.
%20sales%20of%20the%20company%20Processa%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Processa-Pharmaceuticals&v=1772513425136 "Schedule of future (projected) sales of the company Processa Pharmaceuticals")
Future (projected) sales of companies in the market segment - Breast cancer
Processa Pharmaceuticals is an oncology company developing drugs to treat breast and other cancers. This chart shows expectations for the oncology sector. It reflects the enormous need for new and more effective treatments, which is driving the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Breast-cancer&v=1772513425156 "Schedule of future (projected) sales of companies in the market segment - Breast cancer")
Future (projected) sales of the market as a whole
Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing drugs to treat oncology conditions with unmet needs. Its valuation is dependent on the success of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital to fund risky but potentially breakthrough oncology research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513425159 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Processa Pharmaceuticals
Processa Pharmaceuticals specializes in rescuing and refining promising oncology drugs abandoned by other companies. This chart illustrates the profitability of this unique business model. Success depends on the correct selection of candidates and the efficient execution of clinical trials.
Market segment marginality - Breast cancer
Processa Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of cancer, including breast cancer. For a clinical-stage company, this chart is important as an indicator of potential. It reflects the average profitability in the oncology sector that Processa aims to achieve if its drugs are successfully brought to market.
Market marginality as a whole
Processa Pharmaceuticals is a clinical-stage pharmaceutical company specializing in cancer treatments. This overall market profitability chart is irrelevant to the company. Its future depends solely on the results of clinical trials and its ability to demonstrate the efficacy of its drugs in the treatment of oncological diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Processa Pharmaceuticals
Processa Pharmaceuticals is a pharmaceutical company focused on developing oncology drugs. This graph shows a small team managing clinical trials. Their model outsources many functions, allowing them to maintain a lean staff.
Share of the company's employees Processa Pharmaceuticals within the market segment - Breast cancer
Processa Pharmaceuticals specializes in developing drugs for the treatment of cancer, particularly breast cancer. This chart shows the percentage of leading oncologists, pharmacologists, and clinicians focused on this issue that the company attracts. It reflects its concentration of scientific expertise to help millions of patients.
Number of employees in the market segment - Breast cancer
Processa Pharmaceuticals is a biopharmaceutical company developing drugs to treat oncological diseases, particularly breast cancer. This chart illustrates how focused pharmaceutical research can be. Combating specific types of cancer requires the involvement of highly specialized scientists and physicians.
Number of employees in the market as a whole
Processa Pharmaceuticals focuses on cancer treatment, particularly breast cancer. This is a socially significant area that attracts significant attention and investment. This graph reflects the overall labor market, where healthcare and biopharmaceuticals are among the largest and fastest-growing sectors, constantly creating new jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Processa Pharmaceuticals (PCSA)
Processa Pharmaceuticals is a biotech company specializing in oncology. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its drug candidates and their progress through clinical trials. The chart demonstrates the high future value the market is pricing into these developments.
%20of%20the%20company%20Processa%20Pharmaceuticals%20(PCSA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Processa-Pharmaceuticals-PCSA&v=1772513425317 "Chart of market capitalization per employee (in thousands of dollars) of the company Processa Pharmaceuticals (PCSA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Breast cancer
Processa Pharmaceuticals specializes in cancer treatments, particularly breast cancer. In oncology, a company's value is directly linked to the success of clinical trials. The chart shows how investors assess the potential of their developments and the scientific team behind them.
%20by%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Breast-cancer&v=1772513425330 "Market capitalization per employee (in thousands of dollars) by market segment - Breast cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
Processa Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of oncology. This chart shows the average market value generated by one developer, illustrating how the market values its clinical development pipeline.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513425336 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Processa Pharmaceuticals (PCSA)
Processa Pharmaceuticals is a clinical-stage biotech company with no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to conduct R&D and clinical trials.
%20Chart%20Processa%20Pharmaceuticals%20(PCSA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Processa-Pharmaceuticals-PCSA&v=1772513425338 "Company Profit Per Employee (in thousands of dollars) Chart Processa Pharmaceuticals (PCSA)")
Profit per employee (in thousands of dollars) in the market segment - Breast cancer
Processa Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of oncological diseases, particularly breast cancer. Being in clinical trials, it is likely to report negative earnings per employee, reflecting significant investments in its scientific team and long-term research in anticipation of commercial success.
%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Breast-cancer&v=1772513425351 "Chart of profit per employee (in thousands of dollars) in the market segment - Breast cancer")
Profit per employee (in thousands of dollars) for the market as a whole
Processa Pharmaceuticals (PCSA) is a clinical-stage biopharmaceutical company developing drugs for cancer (such as Next Generation Capecitabine) and rare diseases. It's an R&D company. This chart shows the market average dollar return per employee. For PCSA (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513425354 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Processa Pharmaceuticals (PCSA)
Processa Pharmaceuticals is a clinical-stage oncology company focused on breast cancer treatment. This chart is a glimpse into the future. Low current values are normal for biotech, but they could change dramatically if clinical trials are successful and the drug is approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Processa-Pharmaceuticals-PCSA&v=1772513425382 "Sales chart per company employee Processa Pharmaceuticals (PCSA)")
Sales per employee in the market segment - Breast cancer
Processa Pharmaceuticals is a clinical-stage biotech company focused on treating cancer and other diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Processa's staff.
Sales per employee for the market as a whole
Processa Pharmaceuticals is a clinical-stage biotech company focused on treating cancer and rare diseases. The company has no commercial products or revenue, which is irrelevant. Its value lies in the potential of its R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Processa Pharmaceuticals (PCSA)
Processa Pharmaceuticals is a biotech company attempting to revive and improve old, failed oncology drugs. This chart shows the odds that this strategy won't work. The bears believe these "old" molecules have no chance of proving their effectiveness in modern clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Processa-Pharmaceuticals-PCSA&v=1772513425465 "Short Shares Chart for the Company Processa Pharmaceuticals (PCSA)")
Shares shorted by market segment - Breast cancer
Processa Pharmaceuticals is a biopharmaceutical company developing drugs to treat oncology diseases, particularly breast cancer, targeting metastases. This chart reflects the total volume of short positions in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials in oncology.
Shares shorted by the overall market
Processa Pharmaceuticals is a clinical-stage biotech developing cancer treatments. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance the "burning" of cash. They are selling PCSA shares, fearing the company will lack the capital to complete expensive oncology trials amid market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Processa Pharmaceuticals (PCSA)
Processa Pharmaceuticals is a biotech company that rescues and refines abandoned drugs, using them to treat cancer in specific patient groups. This chart tracks how investors view their clinical data, showing "overheated" (above 70) on positive news or "oversold" (below 30) when there are delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Processa-Pharmaceuticals-PCSA&v=1772513425522 "RSI 14 indicator chart for the company's stock Processa Pharmaceuticals (PCSA)")
RSI 14 Market Segment - Breast cancer
Processa Pharmaceuticals is a biotech company developing drugs to treat oncology diseases, including breast cancer, using its PCSA platform. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated.
RSI 14 for the overall market
For Processa Pharmaceuticals, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PCSA (Processa Pharmaceuticals)
Processa Pharmaceuticals is a biotech company developing drugs to treat oncology. This chart shows the average target price. Analysts' forecasts are based on an assessment of the clinical data for its lead candidates, regulatory prospects, and the potential market size for its therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PCSA-Processa-Pharmaceuticals&v=1772513425576 "A chart showing analyst consensus forecasts for the expected stock price. PCSA (Processa Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price PCSA (Processa Pharmaceuticals)
Processa Pharmaceuticals is a biotech company that specializes in "rescue" drugs. They take existing molecules and improve them for cancer treatment. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this R&D strategy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PCSA-Processa-Pharmaceuticals&v=1772513425591 "A chart showing the difference between the consensus forecast and the actual stock price. PCSA (Processa Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Breast cancer
Processa Pharmaceuticals is a biotech company that "rescues" R&D projects. It takes drugs that have failed in one trial and repurposes them for cancer treatment. This chart shows general expectations for the breast cancer sector, reflecting whether experts believe in this "second chance" R&D model.
Analysts' consensus forecast for the overall market share price
Processa Pharmaceuticals (PCSA) is a clinical-stage biopharmaceutical company focused on cancer treatment. Their approach is not to kill tumors, but to "normalize" them, making them susceptible to chemotherapy. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Processa Pharmaceuticals
Processa is a drug rescuer. Rather than scouting for new candidates, it's a biotech that acquires abandoned drugs (those that haven't passed clinical trials) and attempts to improve them (using its PCS platform) to revive them for cancer treatment. This chart is a summary indicator of their R&D arbitrage, reflecting their ability to select winners and their progress in clinical trials.
AKIMA Market Segment Index - Breast cancer
Processa (PCSA) is a drug optimizer. Rather than searching for new molecules, the biotech company takes existing drugs and improves their profile (safety, dosage) using a regulatory approach (PCS12852 for cancer). This chart shows the average index for the segment, helping to assess how this smart R&D strategy compares to the average.
The AKIM Index for the overall market
Processa Pharmaceuticals is a company developing cancer treatments by improving the safety and efficacy of existing chemotherapy drugs (Capecitabine). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this drug improvement strategy compares to overall economic trends.
